title: Human amniotic fluid-derived stem cells expressing cytosine deaminase and thymidine kinase inhibits the growth of breast cancer cells in cellular and xenograft mouse models.
abstract: As human amniotic fluid-derived stem cells (hAFSCs) are capable of multiple lineage differentiation, extensive self-renewal and tumor targeting, they may be valuable for clinical anticancer therapies. In this study, we used hAFSCs as vehicles for targeted delivery of therapeutic suicide genes to breast cancer cells. hAFSCs were engineered to produce AF2.CD-TK cells in order to express two suicide genes encoding bacterial cytosine deaminase (CD) and herpes simplex virus thymidine kinase (HSV-TK) that convert non-toxic prodrugs, 5-fluorocytosine (5-FC) and mono-phosphorylate ganciclovir (GCV-MP), into cytotoxic metabolites, 5-fluorouracil (5-FU) and triphosphate ganciclovir (GCV-TP), respectively. In cell viability test in vitro, AF2.CD-TK cells inhibited the growth of MDA-MB-231 human breast cancer cells in the presence of the 5-FC or GCV prodrugs, or a combination of these two reagents. When the mixture of 5-FC and GCV was treated together, an additive cytotoxic effect was observed in the cell viability. In animal experiments using female BALB/c nude mouse xenografts, which developed by injecting MDA-MB-231 cells, treatment with AF2.CD-TK cells in the presence of 5-FC and GCV significantly reduced tumor volume and weight to the same extent seen in the mice treated with 5-FU. Histopathological and fluorescent staining assays further showed that AF2.CD-TK cells were located exactly at the site of tumor formation. Furthermore, breast tissues treated with AF2.CD-TK cells and two prodrugs maintained their normal structures (for example, the epidermis and reticular layers) while breast tissue structures in 5-FU-treated mice were almost destroyed by the potent cytotoxicity of the drug. Taken together, these results indicate that AF2.CD-TK cells can serve as excellent vehicles in a novel therapeutic cell-based gene-directed prodrug system to selectively target breast malignancies.
authors.affiliation: Laboratory of Veterinary Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
authors.forename: N-H
authors.initials: NH
authors.lastname: Kang
authors.forename: K-A
authors.initials: KA
authors.lastname: Hwang
authors.forename: B-R
authors.initials: BR
authors.lastname: Yi
authors.forename: H J
authors.initials: HJ
authors.lastname: Lee
authors.forename: E-B
authors.initials: EB
authors.lastname: Jeung
authors.forename: S U
authors.initials: SU
authors.lastname: Kim
authors.forename: K-C
authors.initials: KC
authors.lastname: Choi
mesh_terms: D000653:Amniotic Fluid / Q000166:cytology*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002633:Chemotaxis; D043525:Cytosine Deaminase / Q000096:biosynthesis* / Q000235:genetics; D004926:Escherichia coli / Q000201:enzymology; D005260:Female; D005437:Flucytosine / Q000008:administration & dosage / Q000494:pharmacology; D015774:Ganciclovir / Q000008:administration & dosage / Q000494:pharmacology; D005818:Genetic Engineering; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D011355:Prodrugs / Q000008:administration & dosage / Q000494:pharmacology; D018139:Simplexvirus / Q000201:enzymology; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000201:enzymology*; D013937:Thymidine Kinase / Q000096:biosynthesis* / Q000235:genetics; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D011355:Prodrugs; D005437:Flucytosine; D013937:Thymidine Kinase; D043525:Cytosine Deaminase; D015774:Ganciclovir